MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by CenterBook Partners LP

CenterBook Partners LP increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 48.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 867,009 shares of the company's stock after acquiring an additional 281,923 shares during the period. CenterBook Partners LP owned approximately 0.82% of MaxCyte worth $3,607,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Franklin Resources Inc. purchased a new stake in shares of MaxCyte in the third quarter valued at approximately $260,000. Barclays PLC raised its position in MaxCyte by 329.3% during the third quarter. Barclays PLC now owns 165,765 shares of the company's stock worth $645,000 after acquiring an additional 127,156 shares during the period. Geode Capital Management LLC grew its position in shares of MaxCyte by 2.0% in the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock valued at $9,628,000 after purchasing an additional 47,960 shares during the period. State Street Corp raised its position in shares of MaxCyte by 5.1% during the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company's stock worth $8,827,000 after purchasing an additional 111,066 shares during the last quarter. Finally, Rice Hall James & Associates LLC purchased a new position in MaxCyte in the 4th quarter valued at about $1,098,000. Hedge funds and other institutional investors own 68.81% of the company's stock.

MaxCyte Price Performance

Shares of MXCT stock traded up $0.10 on Tuesday, hitting $2.70. The stock had a trading volume of 1,013,223 shares, compared to its average volume of 529,169. The company's 50 day moving average price is $3.29 and its 200-day moving average price is $3.76. MaxCyte, Inc. has a 1 year low of $2.21 and a 1 year high of $5.26. The firm has a market capitalization of $287.05 million, a P/E ratio of -7.94 and a beta of 1.39.

Wall Street Analyst Weigh In

MXCT has been the subject of several research reports. Stifel Nicolaus dropped their price objective on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price target on MaxCyte and gave the stock a "buy" rating in a report on Wednesday, March 12th.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.